SIGN UP
LOG IN
News
CARsgen Therapeutics Holdings
--
--
0.00%
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0602-0606)?
Weekly Report · 4d ago
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0526-0530)?
Weekly Report · 06/01 22:00
CARsgen Therapeutics Holdings Limited's (HKG:2171) biggest owners are retail investors who got richer after stock soared 7.7% last week
Simply Wall St · 05/26 22:57
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0519-0523)?
Weekly Report · 05/25 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0512-0516)?
Weekly Report · 05/18 22:00
CARSGEN ANNOUNCES PRELIMINARY CLINICAL DATA FOR ALLOGENEIC BCMA CAR-T CT0596, DEMONSTRATING FAVORABLE SAFETY AND EFFICACY
Reuters · 05/12 00:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0505-0509)?
Weekly Report · 05/11 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0428-0502)?
Weekly Report · 05/04 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0421-0425)?
Weekly Report · 04/27 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0414-0418)?
Weekly Report · 04/20 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0407-0411)?
Weekly Report · 04/13 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0331-0404)?
Weekly Report · 04/06 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0324-0328)?
Weekly Report · 03/30 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0317-0321)?
Weekly Report · 03/23 22:00
CARSGEN THERAPEUTICS HOLDINGS FY NET INCOME RMB -798 MILLION
Reuters · 03/18 11:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0310-0314)?
Weekly Report · 03/16 22:00
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0303-0307)?
Weekly Report · 03/09 22:00
CARSGEN'S CLAUDIN18.2 CAR-T THERAPY SATRI-CEL GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA
Reuters · 03/03 00:15
Weekly Report: what happened at CARsgen Therapeutics Holdings last week (0224-0228)?
Weekly Report · 03/02 22:00
CARSGEN THERAPEUTICS INTRODUCED ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PRODUCTS DEVELOPMENT IN MAINLAND CHINA
Reuters · 02/25 13:01
About CARsgen Therapeutics Holdings
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
MoreRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.